Update on evidence for treatment with ranolazine in stable angina

Federico Carbone1, Fabrizio Montecucco, François Mach

  • 1Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Switzerland; fedric8@gmail.com.

Swiss Medical Weekly
|October 29, 2013
PubMed

Insights

Ranolazine, a new drug for chronic angina, works by inhibiting the late sodium current. This mechanism improves heart function and may also prevent arrhythmias, offering new therapeutic options.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Chronic angina presents a significant public health challenge due to poor prognosis and high treatment costs.
  • Ranolazine is a recently approved medication for managing chronic angina.

Purpose of the Study:

  • To review current evidence on ranolazine for chronic angina.
  • To discuss the therapeutic potential of ranolazine based on recent research.

Main Methods:

  • Literature review of clinical and experimental studies on ranolazine.
  • Analysis of ranolazine's molecular mechanism of action.

Main Results:

  • Ranolazine's primary mechanism involves inhibiting the late sodium current (late Na+ current) during cardiac action potentials.
  • This inhibition may improve myocardial oxygen consumption, diastolic function, and coronary blood flow.
  • The mechanism also suggests potential antiarrhythmic properties for ranolazine.

Conclusions:

  • Ranolazine demonstrates promising therapeutic effects in chronic angina.
  • Its unique mechanism offers potential benefits beyond symptom relief, including antiarrhythmic effects.
  • Further research is ongoing to fully elucidate ranolazine's role in cardiovascular treatment.

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
496
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
567
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
502
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
487